Conferences

1-Year Data on Omidubicel Shows Sustained Benefits, Reduced Infection Rates

May 2nd 2022

There was a continued trend toward improvement of overall survival with omidubicel at 73% compared with UCBT at 60%.

ZUMA-7 Axi-Cel Superiority Calls for Treatment Paradigm Shift in R/R LBLC

April 27th 2022

The analysis of data from ZUMA-7 demonstrated significant efficacy for axi-cel over second-line standard treatment.

Axi-Cel, Tisa-Cel Have Comparable Efficacy in Follicular Lymphoma, Analysis Shows

April 26th 2022

Tisa-cel was associated with a more favorable safety profile in the analysis.

Durable Response Seen With Axi-Cel in Non-Hodgkin Lymphoma

April 25th 2022

In this population, median progression-free survival was nearly 40 months.

NKT Cell Therapy KUR-502 Effective for B-Cell Malignancies

April 25th 2022

KUR-502 elicited promising response rates for patients with relapsed or refractory B-cell malignancies in a phase 1 study.

T-allo10 Cell Infusion After Haploidentical HSCT Is Safe, Well-Tolerated, Prelim Data Show

April 25th 2022

The treatment seeks to improve immune reconstitution and graft-versus-leukemia immune response without increasing the risk of GvHD in children and young adults with hematologic malignancies.

Off the Shelf NK Cell Therapy Feasible in R/R Acute Myeloid Leukemia, Myelodysplastic Syndrome

April 25th 2022

Preliminary findings from the phase 1 clinical trial demonstrate good cell persistence and expansion in vivo.

Real-World Experience With Beti-cel for Patients With TDT Is Consistent With Trials

April 25th 2022

The real-world data support the recently published results from a phase 3 study, which showed most patients achieved transfusion independence.

LentiGlobin for Sickle Cell Disease: 24-Month Follow-Up Yields Sustained QOL Outcomes

April 25th 2022

The greatest improvements were seen in the Pain, Fatigue, and Physical Functioning domains.

Axi-cel as Frontline Therapy for High-Risk Large B-cell Lymphoma Produces Encouraging Responses

April 25th 2022

In 37 evaluable patients, the objective response rate in the study was 89% (95% CI, 75%-97%) with complete responses in 78%.